LDS/Medical Tests/Factor XIII (F13A1) V34L Genetic Variation Analysis

Factor XIII (F13A1) V34L Genetic Variation Analysis

Factor XIII, also known as fibrin stabilizing factor, is a tetrameric protein consisting of two catalytic subunits (FXIII A) and two inhibitory subunits (FXIII B). It is converted into its active form, FXIIIa, by thrombin with calcium. Deficiency of FXIII results in severe bleeding. Its function is to stabilize fibrin by cross-linking the alpha and gamma chains of fibrin. In addition, FXIIIa protects the newly formed clot by cross-linking alpha (2)-plasmin inhibitor to fibrin. FXIIIa also inhibits platelet adhesion to fibrin, thereby inhibiting further clot growth.

The Factor XIII (F13A) V34L genetic variant is an autosomal dominant polymorphism identified in the FXIII A subunit gene resulting in a G to T polymorphism in exon 2. This single point genetic variation results in a valine to leucine amino acid change at position 34. The Val 34 leu polymorphism increases the rate of factor XIII activation by thrombin. An increased rate of factor XIII activation results in premature depletion of FXIIIa and an increase in fibrinostabilization. V34L also affects the structure of the cross-linked fibrin clot. At high fibrinogen concentrations, fibrin clots of V34L carriers have looser structure and thicker fibers and are degraded faster by fibrinolysis, thus offering protection against thrombotic events.

Protective effects from venous thrombosis (VTE), myocardial infarction (MI), and coronary artery disease (CAD) have been established in Caucasian populations only. Protective effects may be influenced by genetic / non-genetic factors not assessed by this assay. Homozygous factor XIII mutations have been associated with and increased risk for recurrent, spontaneous pregnancy loss.

  • Assessment of genetic susceptibility in patients with a family or personal history of VTE, MI, or CAD.
  • Assessment of therapeutic / preventative therapies for thrombotic events in Caucasians and others with family history
  • As an aid in prevention of recurrent pregnancy loss or miscarriages
  • Heterozygous: One copy of the V34L sequence variant was detected; this is associated with a reduced risk for VTE, MI, and CAD in Caucasian individuals.
  • Homozygous: Two copies of the V34L sequence variant were detected; this is associated with a reduced risk for VTE, MI, and CAD in Caucasian individuals.
  • Protective effect of V34L variant has only been established in Caucasian populations.

Mutation Not Detected (Factor XIII (F13A1) V34L genetic variant not detected).

The presence of the V34L variant in the sample is associated with decreased/reduced risk for VTE, MI, and CAD.

Polymerase chain reaction (PCR) including: mutagenic separated PCR, chemiluminescent PCR with single stranded conformational polymorphism analysis, single nucleotide extension. Other methods include: fluorescence monitoring and rapid automated capillary electrophoresis (RACE), PCR and Allele specific primer extension, PCR with chip array technology, sequencing, pyrosequencing.

Blood collected in EDTA (lavender top tube). 

Stability

  • Ambient: 3-5 days
  • Refrigerated: 5-7 days
  • Frozen: 30 days
Factor V Leiden mutation, Methylenetetrahydrofolate Reductase (MTHF) mutations, Prothrombin (Factor II) mutation, Partial Thromboplastin Time, Factor VIII, Homocysteine, APC resistance profile, D dimer, aPTT, PT, Thrombin-clottable Fibrinogen level, Platelet counts, Bleeding time, Protein S, Protein C, Protein C activity, and Anticardiolipin Antibody, Plasminogen Activator Inhibitor 1 (PAI-1) Mutation, Factor XIII, Mixing Studies, Platelet Antibody.
3-7 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login